Heramed Ltd (HMD) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Heramed Ltd (HMD) has a cash flow conversion efficiency ratio of -3.359x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (AU$-1.27 Million ≈ $-901.06K USD) by net assets (AU$379.12K ≈ $268.26K USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Heramed Ltd (HMD) market capitalisation for the company's overall valuation and market capitalisation.
Heramed Ltd - Cash Flow Conversion Efficiency Trend (2016–2024)
This chart illustrates how Heramed Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Heramed Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Heramed Ltd ranked by their cash flow conversion efficiency. Explore how high is Heramed Ltd's earnings quality to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
PT Sarimelati Kencana Tbk
JK:PZZA
|
0.076x |
|
ROCA INDUSTRY HOLDINGROCK1 S.A.
RO:ROC1
|
N/A |
|
Malton Bhd
KLSE:6181
|
0.035x |
|
Subur Tiasa Holdings Bhd
KLSE:6904
|
0.003x |
|
EP Manufacturing Bhd
KLSE:7773
|
-0.008x |
|
Shenzhen Zhongheng Huafa Co Ltd Class B
SHE:200020
|
-0.032x |
|
Cemat A/S
CO:CEMAT
|
0.066x |
|
Axita Cotton Limited
NSE:AXITA
|
0.010x |
Annual Cash Flow Conversion Efficiency for Heramed Ltd (2016–2024)
The table below shows the annual cash flow conversion efficiency of Heramed Ltd from 2016 to 2024. View Heramed Ltd stock quote for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | AU$1.72 Million ≈ $1.21 Million |
AU$-4.81 Million ≈ $-3.41 Million |
-2.807x | +76.49% |
| 2023-12-31 | AU$466.70K ≈ $330.22K |
AU$-5.57 Million ≈ $-3.94 Million |
-11.940x | -1249.49% |
| 2022-12-31 | AU$2.89 Million ≈ $2.05 Million |
AU$-2.56 Million ≈ $-1.81 Million |
-0.885x | +87.90% |
| 2021-12-31 | AU$441.88K ≈ $312.66K |
AU$-3.23 Million ≈ $-2.29 Million |
-7.314x | -422.60% |
| 2020-12-31 | AU$1.99 Million ≈ $1.41 Million |
AU$-2.78 Million ≈ $-1.97 Million |
-1.399x | -21.16% |
| 2019-12-31 | AU$2.39 Million ≈ $1.69 Million |
AU$-2.76 Million ≈ $-1.95 Million |
-1.155x | -183.85% |
| 2018-12-31 | AU$3.36 Million ≈ $2.37 Million |
AU$-1.37 Million ≈ $-966.34K |
-0.407x | +85.05% |
| 2017-12-31 | AU$201.88K ≈ $142.84K |
AU$-549.66K ≈ $-388.92K |
-2.723x | -71.31% |
| 2016-12-31 | AU$872.17K ≈ $617.12K |
AU$-1.39 Million ≈ $-980.81K |
-1.589x | -- |
About Heramed Ltd
HeraMED Limited, a medical data and technology company, develops, manufactures, and sells home-based maternity monitoring technology in Australia and the United States. It also provides HeraBEAT, a medical device for fetal and maternal heart rate used by pregnant women; and HeraCARE, a remote fetal heart rate monitoring solution. The company has a collaboration agreement with Mayo Clinic for the … Read more